Lexeo Therapeutics, Inc.
Company Stats
- Market Cap
- $277.3M
- as of Sep 30, 2026
- Shares Outstanding
- 82.0M
- Free Float
- 99.0%
Income Statement
- Operating Income
- -$109.3M
- Net Income
- -$100.0M
- EBITDA
- -$109.0M
Cash Flow
- Free Cash Flow
- -$99.0M
- FCF Yield
- -35.7%
- Owner FCF Yield
- -40.1%
Balance Sheet
- Cash & Equivalents
- $63.0M
Returns & Capital
- SBC, 3Y Avg
- $9.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$99.0M | — |
| FY2024 | — | -$81.6M | — |
| FY2023 | — | -$59.6M | — |
| FY2022 | $654,000 | -$55.2M | -8445.3% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 6, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Companies Report Firm Demand, Relentless Cost Pressure